Wainua is a medication designed to reduce levels of apolipoprotein B-100 (ApoB-100) [1]. For eligible patients, a savings program may be available to help reduce out-of-pocket costs [1].
How can I find out about savings for Wainua?
Information regarding savings programs for Wainua is typically provided by the manufacturer or through healthcare provider channels. Eligible patients can inquire with their doctor's office or directly with the pharmaceutical company behind Wainua for details on how to enroll in any available savings programs [1]. These programs often have specific eligibility requirements.
What is Wainua used for?
Wainua is indicated for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who are on maximally tolerated statin therapy [1]. It works by lowering ApoB-100 levels, which is a key component of LDL cholesterol and a marker for cardiovascular risk [1].
Are there other treatments for high cholesterol?
Yes, there are various other treatments available for high cholesterol, including statins, ezetimibe, PCSK9 inhibitors, and bile acid sequestrants [2]. Wainua represents a newer class of medication targeting specific lipid pathways. The choice of treatment depends on individual patient factors, including the type of hypercholesterolemia, existing cardiovascular disease, and response to other therapies [2].
What are the potential side effects of Wainua?
Common side effects reported in clinical trials for Wainua include injection site reactions, upper respiratory tract infections, dizziness, and nausea [1]. Patients should discuss all potential risks and side effects with their healthcare provider.
How is Wainua administered?
Wainua is administered as a subcutaneous injection [1]. The recommended dose and frequency will be determined by a healthcare professional.
What is the mechanism of action for Wainua?
Wainua is an antisense oligonucleotide that targets the messenger RNA (mRNA) for apolipoprotein C-III (ApoC-III) [1]. ApoC-III is a protein that inhibits triglyceride-rich lipoprotein (TRL) clearance. By reducing ApoC-III levels, Wainua increases the activity of lipolytic enzymes, leading to enhanced clearance of TRLs and a reduction in ApoB-100 levels [1].
When did Wainua become available?
Wainua received FDA approval in December 2023 [3].
Are there any patient assistance programs for medications like Wainua?
Beyond manufacturer-specific savings programs, various foundations and organizations offer patient assistance programs for prescription medications to help individuals who face financial challenges in affording their treatment [4]. These programs may have different criteria for eligibility.
What is the difference between Wainua and PCSK9 inhibitors?
Both Wainua and PCSK9 inhibitors are used to lower LDL cholesterol in certain patient populations, but they work through different mechanisms. PCSK9 inhibitors, such as evolocumab and alirocumab, block the PCSK9 protein, which prevents the degradation of LDL receptors in the liver, thereby increasing LDL receptor activity and lowering LDL cholesterol [2]. Wainua, on the other hand, targets ApoC-III to enhance TRL clearance and indirectly reduce ApoB-100.
Sources
1. DrugPatentWatch.com
2. National Heart, Lung, and Blood Institute. (n.d.). Cholesterol Medications.
3. FDA. (2023, December 22). FDA approves Wainua (eplontersen) for heterozygotes familial hypercholesterolemia and clinical atherosclerotic cardiovascular disease.
4. Patient Access Network (PAN) Foundation. (n.d.).